China

China

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
7.83 (6.95 - 8.75) 2019 Modelled IHME
7.9 (7.02 - 8.82) 2018 Modelled IHME
8.02 (7.11 - 8.94) 2017 Modelled IHME
8.23 (7.31 - 9.10) 2016 Modelled IHME
8.44 (7.53 - 9.34) 2015 Modelled IHME
8.57 (7.66 - 9.45) 2014 Modelled IHME
8.66 (7.76 - 9.57) 2013 Modelled IHME
8.75 (7.88 - 9.63) 2012 Modelled IHME
8.84 (7.97 - 9.75) 2011 Modelled IHME
8.95 (8.09 - 9.88) 2010 Modelled IHME
9.1 (8.22 - 10.03) 2009 Modelled IHME
9.28 (8.37 - 10.22) 2008 Modelled IHME
9.47 (8.54 - 10.44) 2007 Modelled IHME
9.69 (8.71 - 10.68) 2006 Modelled IHME
9.92 (8.91 - 10.94) 2005 Modelled IHME
10.24 (9.17 - 11.30) 2004 Modelled IHME
10.64 (9.46 - 11.80) 2003 Modelled IHME
11.04 (9.76 - 12.30) 2002 Modelled IHME
11.36 (10.01 - 12.69) 2001 Modelled IHME
11.51 (10.14 - 12.86) 2000 Modelled IHME
11.54 (10.23 - 12.83) 1999 Modelled IHME
11.56 (10.30 - 12.81) 1998 Modelled IHME
11.57 (10.34 - 12.77) 1997 Modelled IHME
11.58 (10.39 - 12.77) 1996 Modelled IHME
11.6 (10.41 - 12.76) 1995 Modelled IHME
11.63 (10.47 - 12.78) 1994 Modelled IHME
11.68 (10.50 - 12.82) 1993 Modelled IHME
11.75 (10.55 - 12.90) 1992 Modelled IHME
11.82 (10.58 - 13.01) 1991 Modelled IHME
11.91 (10.61 - 13.14) 1990 Modelled IHME
7.18 (5.85 - 8.69) 2015 Modelled WHO
9.75 (4.49 - 17.85) 1992 Survey/reported Xia et al, 1996
5.49 (5.47 - 5.50) 2013 Modelled Schweitzer et al, 2015
7.2 (6.70 - 7.70) 2006 Survey/reported Liang et al, 2009
6.89 (5.84 - 7.95) 2017 Modelled Wang et al, 2019
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.42 (0.34 - 0.51) 2019 Modelled IHME
0.43 (0.35 - 0.51) 2018 Modelled IHME
0.44 (0.35 - 0.52) 2017 Modelled IHME
0.44 (0.36 - 0.53) 2016 Modelled IHME
0.45 (0.37 - 0.54) 2015 Modelled IHME
0.47 (0.38 - 0.55) 2014 Modelled IHME
0.48 (0.39 - 0.57) 2013 Modelled IHME
0.5 (0.41 - 0.59) 2012 Modelled IHME
0.52 (0.43 - 0.61) 2011 Modelled IHME
0.55 (0.46 - 0.65) 2010 Modelled IHME
0.61 (0.50 - 0.71) 2009 Modelled IHME
0.71 (0.59 - 0.83) 2008 Modelled IHME
0.85 (0.71 - 1) 2007 Modelled IHME
1.05 (0.87 - 1.23) 2006 Modelled IHME
1.29 (1.07 - 1.51) 2005 Modelled IHME
2.21 (1.81 - 2.62) 2004 Modelled IHME
4 (3.26 - 4.81) 2003 Modelled IHME
6.08 (4.96 - 7.32) 2002 Modelled IHME
7.83 (6.40 - 9.43) 2001 Modelled IHME
8.65 (7.10 - 10.33) 2000 Modelled IHME
8.78 (7.26 - 10.44) 1999 Modelled IHME
8.88 (7.39 - 10.47) 1998 Modelled IHME
8.95 (7.47 - 10.47) 1997 Modelled IHME
9 (7.53 - 10.50) 1996 Modelled IHME
9.05 (7.57 - 10.56) 1995 Modelled IHME
9.09 (7.62 - 10.62) 1994 Modelled IHME
9.14 (7.65 - 10.65) 1993 Modelled IHME
9.18 (7.63 - 10.75) 1992 Modelled IHME
9.21 (7.65 - 10.81) 1991 Modelled IHME
9.23 (7.66 - 10.84) 1990 Modelled IHME
0.83 (0.56 - 1.18) 2015 Modelled WHO
0.3 2014 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
62 (58 - 67) 2019 Modelled IHME
63 (58 - 67) 2018 Modelled IHME
63 (59 - 67) 2017 Modelled IHME
63 (59 - 67) 2016 Modelled IHME
64 (60 - 67) 2015 Modelled IHME
64 (60 - 68) 2014 Modelled IHME
64 (61 - 68) 2013 Modelled IHME
65 (61 - 68) 2012 Modelled IHME
65 (62 - 68) 2011 Modelled IHME
65 (62 - 69) 2010 Modelled IHME
65 (62 - 69) 2009 Modelled IHME
65 (62 - 69) 2008 Modelled IHME
65 (62 - 69) 2007 Modelled IHME
65 (62 - 68) 2006 Modelled IHME
65 (62 - 69) 2005 Modelled IHME
66 (62 - 69) 2004 Modelled IHME
66 (63 - 69) 2003 Modelled IHME
66 (63 - 70) 2002 Modelled IHME
67 (63 - 70) 2001 Modelled IHME
67 (64 - 70) 2000 Modelled IHME
67 (64 - 70) 1999 Modelled IHME
67 (63 - 70) 1998 Modelled IHME
67 (63 - 70) 1997 Modelled IHME
67 (63 - 70) 1996 Modelled IHME
66 (63 - 70) 1995 Modelled IHME
66 (63 - 70) 1994 Modelled IHME
66 (63 - 70) 1993 Modelled IHME
66 (62 - 70) 1992 Modelled IHME
66 (62 - 70) 1991 Modelled IHME
66 (62 - 69) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
92 2010 Survey/reported WHO/UNICEF
93 2009 Survey/reported WHO/UNICEF
91 2008 Survey/reported WHO/UNICEF
86 2007 Survey/reported WHO/UNICEF
88 2006 Survey/reported WHO/UNICEF
86 2005 Survey/reported WHO/UNICEF
76 2004 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
95 2008 Survey/reported WHO/UNICEF
92 2007 Survey/reported WHO/UNICEF
91 2006 Survey/reported WHO/UNICEF
84 2005 Survey/reported WHO/UNICEF
79 2004 Survey/reported WHO/UNICEF
75 2003 Survey/reported WHO/UNICEF
70 2002 Survey/reported WHO/UNICEF
65 2001 Survey/reported WHO/UNICEF
60 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
4 (3 - 6) 2015 Survey/reported National Health and Family Planning Commission of the People's Republic of China, 2015.
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.34 (1.06 - 1.67) 2019 Modelled IHME
1.32 (1.05 - 1.65) 2018 Modelled IHME
1.28 (1.02 - 1.59) 2017 Modelled IHME
1.02 (0.81 - 1.27) 2016 Modelled IHME
0.79 (0.62 - 0.98) 2015 Modelled IHME
0.79 (0.63 - 0.99) 2014 Modelled IHME
0.81 (0.64 - 1) 2013 Modelled IHME
0.82 (0.65 - 1.02) 2012 Modelled IHME
0.83 (0.66 - 1.03) 2011 Modelled IHME
0.83 (0.66 - 1.04) 2010 Modelled IHME
0.83 (0.66 - 1.03) 2009 Modelled IHME
0.82 (0.64 - 1.02) 2008 Modelled IHME
0.8 (0.63 - 1) 2007 Modelled IHME
0.79 (0.62 - 0.98) 2006 Modelled IHME
0.79 (0.62 - 0.98) 2005 Modelled IHME
0.8 (0.63 - 1) 2004 Modelled IHME
0.84 (0.65 - 1.04) 2003 Modelled IHME
0.89 (0.69 - 1.11) 2002 Modelled IHME
0.95 (0.75 - 1.19) 2001 Modelled IHME
1.02 (0.80 - 1.28) 2000 Modelled IHME
1.11 (0.88 - 1.38) 1999 Modelled IHME
1.23 (0.99 - 1.52) 1998 Modelled IHME
1.37 (1.11 - 1.69) 1997 Modelled IHME
1.52 (1.23 - 1.85) 1996 Modelled IHME
1.64 (1.33 - 1.99) 1995 Modelled IHME
1.75 (1.42 - 2.13) 1994 Modelled IHME
1.85 (1.50 - 2.27) 1993 Modelled IHME
1.95 (1.57 - 2.40) 1992 Modelled IHME
2.05 (1.64 - 2.52) 1991 Modelled IHME
2.14 (1.71 - 2.65) 1990 Modelled IHME
0.7 (0.50 - 0.80) 2015 Modelled Blach et al, 2017
0.8 (0.20 - 1.20) 2014 Modelled Gower et al, 2014
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.91 (0.81 - 1.03) 2015 Modelled Gao et al, 2015
1.3 (0.40 - 2) 2014 Modelled Gower et al, 2014
3.2 (0.90 - 5.10) 1992 Survey/reported Xia et al, 1996
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
63.3 (52.20 - 73.20) 2019 Modelled Granados-Garcia V et al, 2019
43.1 (27.50 - 58.60) 2015 Modelled Degenhardt L et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
18 (15 - 20) 2019 Modelled IHME
17 (15 - 20) 2018 Modelled IHME
17 (15 - 20) 2017 Modelled IHME
17 (15 - 19) 2016 Modelled IHME
17 (15 - 19) 2015 Modelled IHME
17 (15 - 19) 2014 Modelled IHME
17 (15 - 19) 2013 Modelled IHME
17 (15 - 19) 2012 Modelled IHME
17 (15 - 18) 2011 Modelled IHME
16 (15 - 18) 2010 Modelled IHME
17 (15 - 19) 2009 Modelled IHME
17 (15 - 19) 2008 Modelled IHME
17 (15 - 18) 2007 Modelled IHME
17 (15 - 19) 2006 Modelled IHME
17 (15 - 19) 2005 Modelled IHME
16 (15 - 18) 2004 Modelled IHME
16 (14 - 18) 2003 Modelled IHME
16 (14 - 18) 2002 Modelled IHME
16 (14 - 17) 2001 Modelled IHME
15 (14 - 17) 2000 Modelled IHME
16 (14 - 17) 1999 Modelled IHME
16 (14 - 17) 1998 Modelled IHME
16 (14 - 17) 1997 Modelled IHME
16 (14 - 18) 1996 Modelled IHME
16 (14 - 18) 1995 Modelled IHME
16 (14 - 18) 1994 Modelled IHME
16 (14 - 18) 1993 Modelled IHME
16 (14 - 18) 1992 Modelled IHME
16 (14 - 18) 1991 Modelled IHME
16 (14 - 18) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (3 - 6) 2015 Survey/reported National Health and Family Planning Commission of the People's Republic of China, 2015.
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
7.83 (%)
2019
(6.95 - 8.75(%))
IHME
HCV (RNA/cAg+)
1.34 (%)
2019
(1.06 - 1.67(%))
IHME

Survey/surveillance

HBV (HBsAg+)
7.2 (%)
2006
(6.7 - 7.7(%))
Liang et al, 2009
HCV (anti-HCV)
3.2 (%)
1992
(0.9 - 5.1(%))
Xia et al, 1996

Hepatitis related deaths (national)

Modelled

HBV
162,085
2019
(132,642 - 195,155)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
78,041
2019
(64,365 - 92,118)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.30 (%)
2014, survey/surveillance
WHO WPRO, Woodring J et al, 2017

Prevalence PWID

HCV
63.30 (%)
2019, latest modelled
(52.20 - 73.20(%))
Granados-Garcia V et al, 2019

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
96 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
4
2015
(3 - 6)
National Health and Family Planning Commission of the People's Republic of China, 2015.
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources